<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03305809</url>
  </required_header>
  <id_info>
    <org_study_id>16261</org_study_id>
    <secondary_id>I7S-MC-HBEH</secondary_id>
    <nct_id>NCT03305809</nct_id>
  </id_info>
  <brief_title>A Study of LY3154207 in Participants With Parkinson's Disease Dementia</brief_title>
  <acronym>PRESENCE</acronym>
  <official_title>Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized placebo-controlled trial in individuals with Parkinson's disease dementia to
      evaluate the safety and efficacy of three doses of study drug LY3154207 in participants with
      mild-to-moderate Parkinson's disease dementia treated for 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2017</start_date>
  <completion_date type="Anticipated">July 12, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the CoA composite score of the CDR-CCB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline on the ADCS-CGIC score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the CDR-CCB Power of Attention (PoA) Composite Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline on the CDR-CCB PoA composite score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the 13-item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog13)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the 13-item ADAS-Cog13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Screening in the Montreal Cognitive Assessment (MoCA) Score</measure>
    <time_frame>Screening, Week 12</time_frame>
    <description>Change from Screening in the MoCA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Neuropsychiatric Inventory (NPI) Total Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the NPI total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Epworth Sleepiness Scale (ESS) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the ESS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the MDS-UPDRS total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the PDAQ-15 total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in D-KEFS verbal fluency test score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure (SBP) to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in SBP to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SBP to 8 Hours Post Dose</measure>
    <time_frame>Baseline, 8 Hours Post Dose</time_frame>
    <description>Change from baseline in SBP to 8 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in pulse rate to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate to 8 Hours Post Dose</measure>
    <time_frame>Baseline, 8 Hours Post Dose</time_frame>
    <description>Change from baseline in pulse rate to 8 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Steady-State Trough Plasma Concentrations of LY3154207</measure>
    <time_frame>Week 12</time_frame>
    <description>PK: Steady-State Trough Plasma Concentrations of LY3154207</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Parkinson's Disease Dementia</condition>
  <arm_group>
    <arm_group_label>LY3154207 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3154207 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3154207 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3154207</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3154207 High Dose</arm_group_label>
    <arm_group_label>LY3154207 Mid Dose</arm_group_label>
    <arm_group_label>LY3154207 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have Idiopathic Parkinsons's Disease (PD) per MDS criteria with at least 2 years of PD
             symptoms.

          -  Have dementia as defined by a decline in cognitive function, which in the opinion of
             the investigator has resulted in functional impairment.

          -  Have a score on the MoCA of 10 - 23.

          -  Are Modified Hoehn and Yahr Stages 1 - 4.

          -  Have a blood pressure (BP) or pulse rate at screening and randomization, as determined
             by three sequential BP/pulse rate measurements in a seated position:

               -  Participants &lt;60 years old:

                    1. A mean systolic BP less than or equal to 140 millimeters of mercury (mmHg),
                       a mean diastolic BP less than or equal to 90 mmHg and a mean pulse rate less
                       than or equal 90 beats/minute in a seated position.

                    2. Each of the 3 systolic BP measurement must be less than 180 mmHg

               -  Participants â‰¥60 years old:

                    1. A mean systolic BP less than or equal to 150 mmHg, a mean diastolic BP less
                       than or equal to 90 mmHg and a mean pulse rate less than or equal to 90
                       beats/min in a seated position.

                    2. Each of the 3 systolic BP measurement must be less than 180 mmHg

          -  If on anti-parkinsonian agents, participants must be on stable dosage for at least 4
             weeks prior to baseline.

          -  If on medications affecting cognition (rivastigmine, galantamine, donepezil,
             memantine), participants must be on stable dosage for at least 8 weeks prior to
             baseline.

          -  If on antidepressant medications, participants must be on stable dosage for at least 8
             weeks prior to baseline.

          -  If on Clozapine, quetiapine and pimavanserin to address drug-induced or
             disease-related psychosis, participants must be on stable dosage for 4 weeks prior to
             baseline.

          -  If on anti-hypertensive medications, participants must be on stable dosage for at
             least 3 months prior to screening.

          -  Men should use appropriate contraception.

          -  All participants must have a reliable caregiver who is in frequent contact with the
             participant (defined as at least 10 hours per week) and will accompany the participant
             to screening, baseline, day 7, day 42, day 84 and follow-up.

        Exclusion Criteria:

          -  Are women of childbearing potential.

          -  Have significant central nervous system disease, other than PD, that may affect
             cognition or the ability to complete the study, including but not limited to, other
             dementias (e.g., Alzheimer's disease).

          -  Have a history in the last 6 months of transient ischemic attacks or ischemic stroke.

          -  Have a history of intra cerebral hemorrhage due to hypertension.

          -  Have a history of hypertensive encephalopathy.

          -  Have atypical or secondary parkinsonism due to drugs (e.g., antipsychotics) or disease
             (such as progressive supranuclear palsy, essential tremor, multiple system atrophy
             (e.g. striatonigral degeneration, olivopontocerebellar atrophy), or postencephalitic
             parkinsonism).

          -  Have a current implantable intracranial stimulator or history of intracranial ablation
             surgery (e.g., subthalamic, globus pallidus-internal segment [GPi]).

          -  Have a current or any previous diagnosis of bipolar disorder, schizophrenia, or other
             primary psychotic disorder.

          -  Have poorly controlled psychosis (hallucinations or delusions) that in the opinion of
             the investigator would interfere with the subject's ability to be compliant with the
             study protocol.

          -  Have any other psychiatric disorder that, in the judgment of the investigator, would
             interfere with compliance with the study protocol.

          -  Have a history of substance abuse within the past 1 year (drug categories defined by
             the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition [DSM-5], and/or
             substance dependence within the past 1 year, not including caffeine and nicotine.

          -  Have a Geriatric Depression Scale - Short Form (GDS-S) score of &gt;6 at screening.

          -  Have a serious or unstable medical illness, other than idiopathic PD, including
             cardiovascular, hepatic, respiratory, hematologic, endocrinologic, neurologic, or
             renal disease, or clinically significant laboratory or electrocardiogram (ECG)
             abnormality as determined by the investigator.

               -  Have a history in the last 6 months of exertional angina, unstable angina,
                  myocardial infarction, and acute coronary syndrome.

               -  Have a history of heart failure of either New York Heart Association Class III or
                  IV.

               -  A history of additional risk factors for Torsades de Pointes (TdP; [e.g., chronic
                  hypokalemia, family history of Long QT Syndrome]).

          -  Participants with acute liver disease (e.g. acute viral hepatitis, alcoholic
             hepatitis); participants with a known chronic liver disease (e.g. hepatitis B, C,
             alcoholic liver disease, cirrhosis); alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) equal to or higher than 2X upper limit of normal (ULN); total
             bilirubin (TBL) equal to or higher than 1.5X ULN; (except for participants with
             Gilbert's syndrome); or alkaline phosphatase (ALP) equal to or higher than 2X ULN.

          -  Participants have answered 'yes' to either Question 4 (Active Suicidal Ideation with
             Some Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation
             with Specific Plan and Intent) on the &quot;Suicidal Ideation&quot; portion of the Columbia
             Suicide Severity Rating Scale (C-SSRS)- Children's version, or answer &quot;yes&quot; to any of
             the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt).

          -  Have used antipsychotic medications, with the exception of clozapine, quetiapine,
             pimavanserin in the 6 months prior to screening.

          -  Have used trihexyphenidyl and benztropine in the 4 weeks prior to screening.

          -  Have motor conditions for which the antiparkinsonian treatment is expected to change
             during the course of the study, as well as unpredictable motor fluctuations that in
             the investigator's opinion would interfere with administering assessments.

          -  Are currently taking any medications or food, herbal or dietary supplements that are
             inhibitors (e.g., ketoconazole, grapefruit juice) or strong/moderate inducers of
             CYP3A4 (e.g. rifampicin).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>205-934-2402</phone>
    </contact>
    <investigator>
      <last_name>Amy Amara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dignity Health Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>602-406-8284</phone>
    </contact>
    <investigator>
      <last_name>Ryan Walsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic of Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>480-301-6328</phone>
    </contact>
    <investigator>
      <last_name>Shyamai Mehta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>623-832-6500</phone>
    </contact>
    <investigator>
      <last_name>David Shprecher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona Health Sciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>520-626-6524</phone>
    </contact>
    <investigator>
      <last_name>Scott Sherman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson'S &amp; Movement Disorder Institute</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-378-5062</phone>
    </contact>
    <investigator>
      <last_name>DANIEL TRUONG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>714-456-7720</phone>
    </contact>
    <investigator>
      <last_name>Neal Hermanowicz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network - CNS</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>562-304-1742</phone>
    </contact>
    <investigator>
      <last_name>Omid Omidvar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>323-442-5791</phone>
    </contact>
    <investigator>
      <last_name>Daniel Togasaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Neuroscience Medical Group</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>805-278-4148</phone>
    </contact>
    <investigator>
      <last_name>James Sutton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Neuroscience Health Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>650-723-6469</phone>
    </contact>
    <investigator>
      <last_name>Melaine Lising</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis - Health Systems</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>916-734-6523</phone>
    </contact>
    <investigator>
      <last_name>Lin Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>303-724-8225</phone>
    </contact>
    <investigator>
      <last_name>Samantha Holden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-914-1903</phone>
    </contact>
    <investigator>
      <last_name>Peter McAllister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Healthcare Chase Movement Disorders Center</name>
      <address>
        <city>Vernon</city>
        <state>Connecticut</state>
        <zip>06066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Service</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>302-320-6147</phone>
    </contact>
    <investigator>
      <last_name>Justin Martello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>202-444-6087</phone>
    </contact>
    <investigator>
      <last_name>Fernando Pagan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Julie B. Schwartzbard, MD, PA</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-933-5993</phone>
    </contact>
    <investigator>
      <last_name>Julie Schwartzbard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-392-1818</phone>
    </contact>
    <investigator>
      <last_name>Stuart Isaacson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>352-294-5400</phone>
    </contact>
    <investigator>
      <last_name>Adolfo Ramirez-Zamora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-631-6704</phone>
    </contact>
    <investigator>
      <last_name>Bruno Gallo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VIN - Victor Faradji</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>305-595-4041</phone>
    </contact>
    <investigator>
      <last_name>Victor Faradji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collier Neurologic Specialists</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>239-434-0332</phone>
    </contact>
    <investigator>
      <last_name>John Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>352-629-5800</phone>
    </contact>
    <investigator>
      <last_name>Anette Nieves</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-210-1320</phone>
    </contact>
    <investigator>
      <last_name>Ira Goodman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Associates of Ormond Beach</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>386-676-6340</phone>
    </contact>
    <investigator>
      <last_name>James Scott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>813-396-0768</phone>
    </contact>
    <investigator>
      <last_name>Robert Hauser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>404-778-7777</phone>
    </contact>
    <investigator>
      <last_name>Marian Evatt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Center of Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-881-5800</phone>
    </contact>
    <investigator>
      <last_name>Robert Riesenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-563-2030</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central DuPage Hospital</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>630-933-4056</phone>
    </contact>
    <investigator>
      <last_name>Zoran Grujic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-963-7415</phone>
    </contact>
    <investigator>
      <last_name>Jared Brosch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital &amp; Clinic</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>319-356-4757</phone>
    </contact>
    <investigator>
      <last_name>Nadakumar Narayanan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>913-588-6782</phone>
    </contact>
    <investigator>
      <last_name>Rajesh Pahwa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Neurology</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>207-883-1414</phone>
    </contact>
    <investigator>
      <last_name>Michael Kleinman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>410-328-7809</phone>
    </contact>
    <investigator>
      <last_name>Rainer vonCoelln</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Neurological Associates, PC</name>
      <address>
        <city>Lawrence</city>
        <state>Massachusetts</state>
        <zip>01843</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>978-687-2321</phone>
    </contact>
    <investigator>
      <last_name>Shabbir Abbasi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Neurological Associates, PC</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>978-687-2321</phone>
    </contact>
    <investigator>
      <last_name>Marc Shay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>734-936-7910</phone>
    </contact>
    <investigator>
      <last_name>Kara Wyant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>248-957-8940</phone>
    </contact>
    <investigator>
      <last_name>Aaron Ellenbogen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Professionals</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>636-220-1200</phone>
    </contact>
    <investigator>
      <last_name>Siddharth Kaul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-362-6908</phone>
    </contact>
    <investigator>
      <last_name>Susan Criswell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nevada Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>702-671-5093</phone>
    </contact>
    <investigator>
      <last_name>Eric Farbman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic of Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>702-483-6049</phone>
    </contact>
    <investigator>
      <last_name>Zoltran Mari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>603-650-8354</phone>
    </contact>
    <investigator>
      <last_name>Stephen Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JFK Neuroscience Institute at JFK Medical Center</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>732-321-7000</phone>
    </contact>
    <investigator>
      <last_name>Philip Hanna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of NJ</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>973-850-4622</phone>
    </contact>
    <investigator>
      <last_name>Michelle Papka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Neurological and Neurodevelopmental Health</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>856-346-0005</phone>
    </contact>
    <investigator>
      <last_name>ROGER KURLAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dent Neurological Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>716-250-2000</phone>
    </contact>
    <investigator>
      <last_name>Horace Capote</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adirondack Medical Research</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <zip>12801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>518-798-9401</phone>
    </contact>
    <investigator>
      <last_name>Andrew Garner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>212-263-4838</phone>
    </contact>
    <investigator>
      <last_name>Andrew Feigin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-446-1900</phone>
    </contact>
    <investigator>
      <last_name>Sanjay Iyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>919-668-0209</phone>
    </contact>
    <investigator>
      <last_name>Burton Scott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>336-716-2357</phone>
    </contact>
    <investigator>
      <last_name>Mustafa Siddiqui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>717-531-7670</phone>
    </contact>
    <investigator>
      <last_name>Thyagarajan Subramanian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-503-0370</phone>
    </contact>
    <investigator>
      <last_name>Jay Schneider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>215-829-7512</phone>
    </contact>
    <investigator>
      <last_name>Nabila Dahodwala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>843-792-7262</phone>
    </contact>
    <investigator>
      <last_name>Federico Rodriguez-Porcel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-827-3610</phone>
    </contact>
    <investigator>
      <last_name>Waleed El Feky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Consultants of Dallas, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-750-9977</phone>
    </contact>
    <investigator>
      <last_name>Nirav Pavasia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>713-798-7438</phone>
    </contact>
    <investigator>
      <last_name>Joohi Jimenez-Shahed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-790-3311</phone>
    </contact>
    <investigator>
      <last_name>WILLIAM ONDO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Camila Aguino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Neurology Specialists</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>757-507-0600</phone>
    </contact>
    <investigator>
      <last_name>Karen Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-453-0404</phone>
    </contact>
    <investigator>
      <last_name>Arifulla Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evergreen Professional Plaza</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>425-899-5385</phone>
    </contact>
    <investigator>
      <last_name>Pinky Agarwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Madis</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>608-262-7003</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Shannon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ottawa</city>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.&quot;</name>
      <address>
        <city>Toronto</city>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changchun</city>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dalian</city>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.&quot;</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hangzhou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hangzhou</city>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yancheng</city>
        <zip>224005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Cruz Behavioral PSC</name>
      <address>
        <city>BayamÃ³n</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877982170</phone>
    </contact>
    <investigator>
      <last_name>William Julio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cortex, PSC</name>
      <address>
        <city>Las Piedras</city>
        <zip>00771</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7874130370</phone>
    </contact>
    <investigator>
      <last_name>Christian Schenk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Neurologia Dra. Ivonne Fraga</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877639312</phone>
    </contact>
    <investigator>
      <last_name>Ivonne Fraga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877590306</phone>
    </contact>
    <investigator>
      <last_name>Carmen Serrano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/parkinson-s-disease-dementia/HBEH#?postal=</url>
    <description>A Study of LY3154207 in Participants With Parkinson's Disease Dementia (PRESENCE)</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson disease dementia</keyword>
  <keyword>Parkinson disease</keyword>
  <keyword>Dopamine</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

